Core business drives Allergy Therapeutics' 2008 results
This article was originally published in Scrip
Executive Summary
Allergy Therapeuticshas maintained its strong financial performance, driven largely by its core business in Europe. Preliminary results for the year ended June 30th show double-digit sales growth and further reduced losses through lower R&D spending.